Kalawski Ryszard, Majewski Marcin, Kaszkowiak Eugeniusz, Wysocki Henryk, Siminiak Tomasz
Department of Cardiac Surgery, J. Strus Hospital Poland, Poznan, Poland.
Chest. 2003 May;123(5):1355-60. doi: 10.1378/chest.123.5.1355.
Dysfunction of myocardium as a result of ischemia/reperfusion during coronary artery bypass grafting (CABG) is currently one of the biggest problems in cardiovascular surgery. In previous studies, it has been well established that activated leukocytes and coronary vascular endothelial cells play an important role in the development of cardiac tissue damage during ischemia followed by reperfusion. Interactions between both of these cell types require the expression of adhesion molecules on their surface. In certain conditions, on cell activation, the adhesion proteins may be released from activated cells in soluble form into circulation. The purpose of our study was to establish whether the use of blood cardioplegia modifies plasma levels of soluble intracellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), and soluble L-selectin (sL-selectin) in comparison with crystalloid cardioplegia in patients undergoing CABG.
Patients undergoing CABG were classified into two groups to receive cold crystalloid cardioplegia (St. Thomas' Hospital) or cold blood cardioplegia (method of Buckberg), followed by a "warm-shot" of the solution. Coronary sinus and arterial blood samples were obtained from 50 patients (42 men and 8 women; age range, 34 to 73 years) before aortic cross-clamping, at the beginning of reperfusion, and after 30 min of reperfusion. Plasma levels of soluble adhesion molecules were measured using sensitive enzyme-linked immunosorbent assays.
The transcardiac release of sICAM-1 and sVCAM-1 following myocardial ischemia/reperfusion during CABG was evident in both groups of patients. However, the increase of soluble forms of both of these adhesion proteins was more significant in the group of patients receiving crystalloid cardioplegia. Crystalloid cardioplegia resulted in decreased plasma level of sE-selectin in the coronary sinus blood sample after 30 min of reperfusion. No significant changes in plasma levels of sL-selectin in either group were observed.
Cardioplegia may affect the release of soluble forms of adhesion molecules from ischemic myocardium and modify endothelium activation in patients undergoing CABG.
冠状动脉旁路移植术(CABG)期间因缺血/再灌注导致的心肌功能障碍是目前心血管外科面临的最大问题之一。在先前的研究中,已经明确活化的白细胞和冠状动脉血管内皮细胞在缺血后再灌注期间心脏组织损伤的发生发展中起重要作用。这两种细胞类型之间的相互作用需要其表面粘附分子的表达。在某些情况下,细胞活化时,粘附蛋白可能以可溶性形式从活化细胞释放到循环中。我们研究的目的是确定与接受晶体停搏液的CABG患者相比,使用血液停搏液是否会改变血浆中可溶性细胞间粘附分子-1(sICAM-1)、可溶性血管细胞粘附分子-1(sVCAM-1)、可溶性E-选择素(sE-选择素)和可溶性L-选择素(sL-选择素)的水平。
接受CABG的患者分为两组,分别接受冷晶体停搏液(圣托马斯医院法)或冷血停搏液(巴克伯格法),随后给予一次“温注”溶液。在主动脉阻断前、再灌注开始时以及再灌注30分钟后,从50例患者(42例男性和8例女性;年龄范围34至73岁)获取冠状窦和动脉血样本。使用灵敏的酶联免疫吸附测定法测量血浆中可溶性粘附分子的水平。
两组患者在CABG期间心肌缺血/再灌注后,sICAM-1和sVCAM-1的跨心脏释放均很明显。然而,在接受晶体停搏液的患者组中,这两种粘附蛋白可溶性形式的增加更为显著。晶体停搏液导致再灌注30分钟后冠状窦血样本中sE-选择素的血浆水平降低。两组中sL-选择素的血浆水平均未观察到显著变化。
停搏液可能影响缺血心肌中粘附分子可溶性形式的释放,并改变接受CABG患者的内皮细胞活化。